Daniel R. Schimmel, MD, explains how balloon pulmonary angioplasty (BPA) uses balloons and specialized catheters to open narrowed vessels in the lungs to improve circulation and reduce symptoms…
Nick Norwitz interviews Aseem Malhotra, MD, a consultant cardiologist, on controversial new findings challenging LDL cholesterol’s role as an independent risk factor for heart disease. They discuss data…
NEW YORK (Reuters Health) – Patients who develop acute renal failure (ARF) after undergoing coronary artery bypass grafting have a poorer prognosis if the condition doesn’t resolve within…
NEW YORK (Reuters Health) – The patency of saphenous veins used for coronary artery bypass grafting is better in the 3 months after the operation when patients are…
NEW YORK (Reuters Health) – Stent fractures are not always associated with clinical sequelae, but they do increase the likelihood of in-stent restenosis (ISR) and target lesion revascularization…
NEW YORK (Reuters Health) – Implantable cardioverter-defibrillators (ICDs) used to prevent sudden cardiac death in patients with severe left ventricular dysfunction significantly improve survival in younger patients, but…
NEW YORK (Reuters Health) – Rosuvastatin halves the rate of primary cardiovascular events in patients who have a high global cardiovascular risk profile, according to a post hoc…
Francis G. Spinale, MD, PhD, Medical University of South Carolina, discusses controlling BP using biomarkers to tell us if we should add on antihypertensive therapy. Related Reading Angiotensin-(1-7)…
NEW YORK (Reuters Health) – In patients with mixed dyslipidemia, fenofibric acid added to atorvastatin and ezetimibe results in improved lipid and non-lipid levels, according to a report…
Sandeep Jauhar, MD, cardiologist and author, describes, via his office webcam, the experience of being an intern and the subject of his book, Intern: A Doctor’s Initiation, a…
NEW YORK (Reuters Health) – For patients with rheumatoid arthritis (RA), treatment with anti-tumor necrosis factor (TNF) agents appears to reduce their risk of cardiovascular events, including MI…
NEW YORK (Reuters Health) – Postmenopausal women treated for osteoporosis with the selective estrogen receptor modulator lasofoxifene have a reduced risk of coronary heart disease events, researchers report…
